Celldex/$CLDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Celldex

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Ticker

$CLDX
Sector
Primary listing

Employees

186

Celldex Metrics

BasicAdvanced
$1.7B
-
-$3.01
1.22
-

What the Analysts think about Celldex

Analyst ratings (Buy, Hold, Sell) for Celldex stock.

Bulls say / Bears say

Data from the Phase 2 barzolvolimab study in chronic spontaneous urticaria showed that 41% of patients maintained a complete response seven months post-dosing and 48% reported no impact on quality of life, with a favorable safety profile, supporting ongoing Phase 3 enrollment (Nasdaq[turn1search1]).
As of June 30, 2025, cash, cash equivalents and marketable securities totaled $630.3 million, providing a runway to fund operations through at least 2027 and underlining the company’s financial resilience despite clinical investment (Globe Newswire[turn9search0]).
The pipeline has progressed with global Phase 3 trials underway for barzolvolimab in CSU, a Phase 3 program in chronic inducible urticaria under development, enrollment complete in Phase 2 EoE, and an active Phase 1 trial of CDX-622, demonstrating diversified clinical momentum (Globe Newswire[turn4search1]).
Q2 2025 net loss widened to $56.6 million (−$0.85 per share) versus $35.8 million (−$0.54 per share) in Q2 2024, reflecting a 57.9% year-over-year increase in R&D-driven losses (Nasdaq[turn9search0]).
Total revenue in Q2 2025 plummeted to just $0.7 million, a 72% decline from $2.5 million in Q2 2024, underscoring the company’s continued reliance on grants and service agreements rather than product sales (Nasdaq[turn9search0]).
Celldex warns that significant scale-up of its manufacturing processes may encounter unanticipated technical challenges and require additional FDA-approved validation studies, posing risks to supply continuity and commercialization timelines (SEC 10-Q[turn9search7]).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

Celldex Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Celldex Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CLDX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs